Otsuka Holdings

Diversified pharma; vasopressin-antagonist franchise (tolvaptan)

4578 · TSE · Japan

Public Market Listing

4578TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Otsuka Holdings are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(23 total)
23Total Assets
15Approved
4Phase 3 / Filed
4Phase 1–2 / Early
24Diseases
Quick filter:
Showing 23 of 23 assets
Target & Modality
Approved
Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule
SchizophreniaBipolar Disorder
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Major Depressive DisorderSchizophreniaBipolar Disorder
Bempedoic acid(Nexletol)
Approved
ATP citrate lyaseSmall molecule
Atherosclerotic Cardiovascular Disease
Approved
ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule
Atherosclerotic Cardiovascular Disease
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia
Centanafadine(Simtriyo)
Approved
Serotonin/norepinephrine/dopamine transporterSmall molecule
Attention Deficit Hyperactivity Disorder
Approved
Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Small molecule
Acute Myeloid LeukemiaMyelodysplastic Syndromes
difamilast(Moizerto / Adquey)
Approved
PDE4Small molecule
Atopic Dermatitis
Donidalorsen(Dawnzera)
Approved
Prekallikrein (PKK) mRNARNA / oligonucleotide
Hereditary Angioedema
Approved
CGRP ligandMonoclonal antibody
Migraine
Ponatinib(ICLUSIG)
Approved
BCR-ABL (including T315I)Small molecule
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
rotigotine(Neupro)
Approved
Dopamine receptorsSmall molecule
Parkinson's Disease
Approved
Neprilysin + Angiotensin II receptor (dual)Small molecule
HypertensionHeart Failure
Approved
Vasopressin V2 receptorSmall molecule
Autosomal Dominant Polycystic Kidney Disease
Voclosporin(Lupkynis)
Approved
Calcineurin · Cyclophilin A (leading to calcineurin inhibition)Small molecule
Systemic Lupus ErythematosusLupus Nephritis

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema
Est. primary completion 2026-12 · NCT05392114 · CT.gov ↗
What to watch
difamilast · Moizerto / AdqueyPhase 3Atopic Dermatitis (AD)
Est. primary completion 2026-12 · NCT07173478 · CT.gov ↗
What to watch
2027 (8)
February 2027 (1)
difamilast · Moizerto / AdqueyPhase 3Atopic Dermatitis (AD)
Est. primary completion 2027-02 · NCT07184645 · CT.gov ↗
What to watch
May 2027 (1)
Centanafadine · SimtriyoPhase 3Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Est. primary completion 2027-05-27 · NCT07759154 · CT.gov ↗
What to watch
August 2027 (2)
Centanafadine · SimtriyoPhase 2/3Attention-Deficit Hyperactivity Disorder(ADHD)
Est. primary completion 2027-08 · NCT07086313 · CT.gov ↗
What to watch
Centanafadine · SimtriyoPhase 3Attention-Deficit Hyperactivity Disorder(ADHD)
Est. primary completion 2027-08 · NCT07087327 · CT.gov ↗
What to watch
September 2027 (1)
Brexpiprazole (Rexulti)Phase 3Acute Schizophrenia
Est. primary completion 2027-09 · NCT05325645 · CT.gov ↗
What to watch
December 2027 (3)
Centanafadine · SimtriyoPhase 2/3Attention Deficit Hyperactivity Disorder (ADHD)
Est. primary completion 2027-12 · NCT06931080 · CT.gov ↗
What to watch
Centanafadine · SimtriyoPhase 3Attention Deficit Hyperactivity Disorder (ADHD)
Est. primary completion 2027-12 · NCT06926829 · CT.gov ↗
What to watch
Decitabine/cedazuridine (Inqovi)Phase 2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Est. primary completion 2027-12-31 · NCT04093570 · CT.gov ↗
What to watch
2028 (5)
February 2028 (1)
Ponatinib · ICLUSIGPhase 1/2Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia …
Est. primary completion 2028-02-01 · NCT03934372 · CT.gov ↗
What to watch
March 2028 (1)
UlotarontPhase 3Schizophrenia
Est. primary completion 2028-03 · NCT07225712 · CT.gov ↗
What to watch
October 2028 (1)
UlotarontPhase 3Generalized Anxiety Disorder
Est. primary completion 2028-10-25 · NCT07767903 · CT.gov ↗
What to watch
December 2028 (2)
UlotarontPhase 3Generalized Anxiety Disorder
Est. primary completion 2028-12-06 · NCT07759128 · CT.gov ↗
What to watch
Tolvaptan · SamscaPhase 3Autosomal Recessive Polycystic Kidney (ARPKD)
Est. primary completion 2028-12-28 · NCT04782258 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
UlotarontPhase 3Generalized Anxiety Disorder
Est. primary completion 2029-05-26 · NCT07786454 · CT.gov ↗
What to watch
June 2029 (1)
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema (HAE)
Est. primary completion 2029-06 · NCT07298447 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultUlefnersenFUSION Phase 3 meets primary endpoint
Ionis Pharmaceuticals · Source ↗
24 July 2026ApprovalCentanafadineFDA Boxed Warning on Simtriyo (NDA218145)
US, FDA · FDA · Source ↗
8 April 2026WithdrawalAripiprazole (Abilify MyCite)FDA withdraws approval of NDA 207202 (Federal Register 2026-04546)
US, FDA · Source ↗
23 April 2025ApprovalTolvaptan (Jynarque)First generic tolvaptan (Jynarque strengths) approved for Lupin; US launch 2025-05-13 with 180-day exclusivity
US, FDA · Lupin · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$4.0B$523M$3.4B—report ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$16.5B$2.4B$3.4B—report ↗

Otsuka Pharmaceutical reported revenue of $16,498.34M, up 7.1% YoY, R&D spend of $2,357.84M, up 13.5% YoY, and cash and equivalents of $3,413.87M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$15.4B$2.1B$2.7B—report ↗
2023-FY$14.4B$2.2B$3.6B—report ↗
2022-FY$13.3B$2.1B$3.5B—report ↗